EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-term follow-up of patients with high-risk facial basal cell carcinoma treated with interferon

Vladimir Sánchez, Emilio Carpio, Vicente Eloy Fardales, Belkys Martínez, Ana Iris Arias, Elizabeth Brito, Niurka Bermudez, Yoel Rodríguez

Anais Brasileiros de Dermatologia · 2024

DOI: 10.1016/j.abd.2023.08.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anais Brasileiros de Dermatologia, 2024. Verfasst von Vladimir Sánchez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department. Polyclinic Juana Naranjo Leon, Sancti Spíritus, Cuba. Hauptthemen laut MEDLINE: Basal Cell Carcinoma, Skin Neoplasms, Neoplasm Recurrence, Local, Facial Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Surgery is the treatment of choice for patients with basal cell carcinoma (BCC). When surgery is not a choice, only radiotherapy is recommended for patients with high-risk facial BCC. Interferon could be an acceptable therapeutic option for these patients.

Objective

To evaluate the long-term clinical response to interferon therapy in patients with high-risk facial BCC.

Methods

Patients with high-risk facial BCC were treated with perilesional injections of alpha-2b+ gamma interferons. Those with incomplete clinical response were reevaluated, their residual tumors excised, and declared cured. Patients treated with interferon and those treated with interferon plus surgery were followed for five years. Time to recurrence and the emergence of a new facial BCC were estimated by Kaplan-Meier survival analysis. Adverse events were documented.

Results

This study included 195 participants; 143 (73.3%) showed a complete response (95% CI 67.2‒80.1). Patients developed recurrence after a mean of 55 months (95% CI 53.8‒57.4). The estimated rate of recurrence was 12.3% (95% CI 7.4‒17.1). Patients developed a new BCC after a mean of 52.7 months (95% CI 50.4‒54.9). The estimated rate for development of a new BCC was 20.0% (95% CI 14.4‒25.9). Fifteen (7.7%) patients abandoned the study during follow-up. Adverse events were frequent but moderate or mild; fever and local pain were the most frequent. Study limitations Observational cohort design without a control group for comparison.

Conclusions

Perilesional injections of alpha-2b+ gamma interferons in patients with facial high-risk BCC offer a satisfactory cure rate after five years of follow-up with an acceptable safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Basal Cell CarcinomaSkin NeoplasmsNeoplasm Recurrence, LocalFacial NeoplasmsInterferon alpha-2Interferon-alphaHumansMaleFemaleMiddle AgedFollow-Up StudiesAgedTreatment OutcomeTime FactorsAdultAntineoplastic AgentsKaplan-Meier EstimateAged, 80 and overInterferon-gammaRecombinant Proteins

Stichwörter der Autor:innen

Carcinoma, basal cellDermatologyInterferonsTherapeutics

Substanzen

Interferon alpha-2Interferon-alphaAntineoplastic AgentsInterferon-gammaRecombinant Proteins

Autor:innen und Institutionen

  • Dermatology Department. Polyclinic Juana Naranjo Leon, Sancti Spíritus, Cuba.
  • Department of Biomedical Sciences, Universidad de Ciencias Médicas, Sancti Spíritus, Cuba. Electronic address: emilio.carpio.md@gmail.com.
  • Department of Biomedical Sciences, Universidad de Ciencias Médicas, Sancti Spíritus, Cuba.
  • Dermatology Department, Polyclinic Camilo Cienfuegos, Yaguajay, Sancti Spíritus, Cuba.
  • Dermatology Department, Polyclinic Manuel de Jesús Lara Cantero, Trinidad, Sancti Spíritus, Cuba.
  • Dermatology Department, Center Polyclinic Juana Naranjo Leon, Sancti Spíritus, Cuba.

Zitieren

APA

Sánchez, V., Carpio, E., Fardales, V. E., Martínez, B., Arias, A. I., Brito, E., Bermudez, N., & Rodríguez, Y. (2024). Long-term follow-up of patients with high-risk facial basal cell carcinoma treated with interferon. Anais Brasileiros de Dermatologia. https://doi.org/10.1016/j.abd.2023.08.009

Vancouver

Sánchez V, Carpio E, Fardales VE, Martínez B, Arias AI, Brito E, et al. Long-term follow-up of patients with high-risk facial basal cell carcinoma treated with interferon. Anais Brasileiros de Dermatologia. 2024. doi:10.1016/j.abd.2023.08.009

BibTeX
@article{Snchez2024,
  author = {Sánchez, Vladimir and Carpio, Emilio and Fardales, Vicente Eloy and Martínez, Belkys and Arias, Ana Iris and Brito, Elizabeth and Bermudez, Niurka and Rodríguez, Yoel},
  title = {Long-term follow-up of patients with high-risk facial basal cell carcinoma treated with interferon},
  journal = {Anais Brasileiros de Dermatologia},
  year = {2024},
  doi = {10.1016/j.abd.2023.08.009}
}
Kostenlos starten →